PHAXIAM Therapeutics (PHXM) Short Interest Ratio & Short Volume

Short interest is the volume of PHAXIAM Therapeutics shares that have been sold short but have not yet been covered or closed out. As of February 29th, traders have sold 1,200 shares of PHXM short. 0.01% of PHAXIAM Therapeutics' shares are currently sold short. Learn More on PHAXIAM Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.01% of PHAXIAM Therapeutics' floating shares are currently sold short.

PHAXIAM Therapeutics saw a decrease in short interest in the month of February. As of February 29th, there was short interest totaling 1,200 shares, a decrease of 50.0% from the previous total of 2,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

PHAXIAM Therapeutics currently has issued a total of 3,412,000 shares. Some of PHAXIAM Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. PHAXIAM Therapeutics currently has a public float of 17,310,000 shares.

0.01% of PHAXIAM Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to PHAXIAM Therapeutics: Monopar Therapeutics Inc. (2.01%), Purple Biotech Ltd (0.93%), Plus Therapeutics, Inc. (1.10%), Vaccinex, Inc. (2.99%), PaxMedica, Inc. (9.41%), Vincerx Pharma, Inc. (8.91%), Fresh Tracks Therapeutics, Inc. (0.17%), Exicure, Inc. (2.01%), SeaStar Medical Holding Co. (6.36%), LianBio (0.36%),

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.39 billion), General Motors ($3.88 billion), Super Micro Computer, Inc. ($3.51 billion), Charter Communications, Inc. ($3.22 billion), Occidental Petroleum Co. ($3.13 billion), Tractor Supply ($2.76 billion), Coinbase Global, Inc. ($2.63 billion), Suncor Energy Inc. ($2.48 billion), Moderna, Inc. ($2.04 billion), and Royal Caribbean Cruises Ltd. ($1.87 billion). View all of the most shorted stocks.

Short selling PHXM is an investing strategy that aims to generate trading profit from PHAXIAM Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for PHAXIAM Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PHXM, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PHXM, twice per month. The most recent reporting period available is February, 29 2024.